Newborn Screening for Congenital Hypothyroidism, Congenital Adrenal Hyperplasia, and Glucose-6-Phosphate Dehydrogenase Deficiency for Improving Health Care in India

Abstract Newborn screening (NBS) aims toward early detection of treatable congenital disorders. From January 2008 through December 2017, 13,376 newborns were screened for congenital hypothyroidism (CH), congenital adrenal hyperplasia (CAH), and glucose-6-phosphate dehydrogenase (G6PD) deficiency at Sir Ganga Ram Hospital, India, by measuring G6PD activity, thyroid-stimulating hormone, and 17-hydroxyprogesterone on dried blood specimens. The birth prevalence of 1:2,000 for CH, 1:2,500 for CAH, and 1:125 for G6PD deficiency indicates the latter as the most prevalent. Performance evaluation of testing reveals a robust screening program with 100% sensitivity and >99% specificity. Hence, we recommend NBS for early diagnosis and treatment to prevent adverse outcomes.

[1]  I. Rudan,et al.  Global birth prevalence and mortality from inborn errors of metabolism: a systematic analysis of the evidence , 2018, Journal of global health.

[2]  Icmr Task Force on Inherited Metabolic Disorders.  Newborn Screening for Congenital Hypothyroidism and Congenital Adrenal Hyperplasia , 2018, The Indian Journal of Pediatrics.

[3]  A. Unnikrishnan,et al.  Congenital hypothyroidism - An Indian perspective , 2017 .

[4]  F. Azizi,et al.  Worldwide Recall Rate in Newborn Screening Programs for Congenital Hypothyroidism , 2017, International journal of endocrinology and metabolism.

[5]  K. Moinuddin,et al.  Prevalence of glucose 6 phosphate dehydrogenase (G6PD) deficiency in a community by newborn screening , 2017 .

[6]  B. Zhang,et al.  Molecular diagnosis of Chinese patients with 21-hydroxylase deficiency and analysis of genotype–phenotype correlations , 2017, The Journal of international medical research.

[7]  J. King,et al.  Whole-Genome Screening of Newborns? The Constitutional Boundaries of State Newborn Screening Programs , 2016, Pediatrics.

[8]  R. K. Kishore Kumar,et al.  Newborn Screening for Congenital Adrenal Hyperplasia in India: What Do We Need to Watch Out for? , 2016, The Journal of Obstetrics and Gynecology of India.

[9]  K. Hsiao,et al.  Inherited metabolic disorders: Quality management for laboratory diagnosis. , 2015, Clinica chimica acta; international journal of clinical chemistry.

[10]  M. Nock,et al.  Pediatric Provider Insight Into Newborn Screening for Glucose-6-Phosphate Dehydrogenase Deficiency , 2015, Clinical pediatrics.

[11]  S. Kapoor,et al.  Newborn screening for G6PD deficiency: A 2-year data from North India. , 2015, Indian journal of public health.

[12]  P. Fechner.  Benefits seen with newborn screening for CAH, but false-positives high , 2014, AAP News.

[13]  L. Prosser,et al.  Decision-making process for conditions nominated to the Recommended Uniform Screening Panel: statement of the US Department of Health and Human Services Secretary’s Advisory Committee on Heritable Disorders in Newborns and Children , 2013, Genetics in Medicine.

[14]  M. Dattani,et al.  Cardiovascular risk factors in children and adolescents with congenital adrenal hyperplasia due to 21hydroxylase deficiency , 2014 .

[15]  I. Verma,et al.  Newborn Screening: Need of the Hour in India , 2014, The Indian Journal of Pediatrics.

[16]  W. Lai,et al.  Epidemiology and Clinical Characteristics of Congenital Hypothyroidism in an Asian Population: A Nationwide Population-Based Study , 2012, Journal of epidemiology.

[17]  B. Biswas,et al.  Glucose-6-phosphate dehydrogenase screening of babies born in a tertiary care hospital in West Bengal. , 2012, Indian journal of public health.

[18]  M. Leichsenring,et al.  Efficacy and outcome of expanded newborn screening for metabolic diseases - Report of 10 years from South-West Germany * , 2011, Orphanet journal of rare diseases.

[19]  R. Prasad,et al.  Preliminary Report on Neonatal Screening for Congenital Hypothyroidism, Congenital Adrenal Hyperplasia and Glucose-6-Phosphate Dehydrogenase Deficiency: A Chandigarh Experience , 2010, Indian journal of pediatrics.

[20]  M. Willis,et al.  Robert Guthrie, MD, PhDClinical Chemistry/Microbiology , 2009 .

[21]  E. C. Neto,et al.  Update: newborn screening for endocrinopathies. , 2009, Endocrinology and metabolism clinics of North America.

[22]  Ernest Beutler,et al.  The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis. , 2009, Blood cells, molecules & diseases.

[23]  M. Cappellini,et al.  Glucose-6-phosphate dehydrogenase deficiency , 2008, The Lancet.

[24]  B. Therrell,et al.  Newborn screening in the Asia Pacific region , 2007, Journal of Inherited Metabolic Disease.

[25]  K. Pass,et al.  Increase in congenital hypothyroidism in New York State and in the United States. , 2007, Molecular genetics and metabolism.

[26]  J. Frank.  Diagnosis and management of G6PD deficiency. , 2005, American family physician.

[27]  A. R. R. Devi,et al.  Newborn screening in India , 2004, Indian journal of pediatrics.

[28]  S. Joshi,et al.  High prevalence of G6PD deficiency in Vataliya Prajapati community in western India. , 2001, Haematologia.

[29]  P. White,et al.  Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. , 2000, Endocrine reviews.

[30]  S. Sivasankaran,et al.  Mass newborn screening for glucose-6-phosphate dehydrogenase deficiency in Singapore. , 1999, The Southeast Asian journal of tropical medicine and public health.

[31]  H. Notopuro,et al.  Glucose-6-phosphate dehydrogenase deficiency. , 1972, Paediatrica Indonesiana.